SAN DIEGO, March 7, 2018 /PRNewswire/ -- Metacrine, Inc., an innovative biotechnology company focused on drug development, today announced that Ken Song, MD, President and CEO, will participate in two upcoming investor conferences.
Dr. Song will give a corporate presentation and participate in a NASH panel discussion at the 30th Annual ROTH Conference taking place at the Ritz-Carlton in Dana Point, CA. The corporate presentation will take place Monday, March 12, 2018 at 3:30 p.m. Pacific in Green Salon-3. The panel presentation "Not All Fruits are the Same, But What About FXR Agonists?" will take place earlier that same day at 10 a.m. Pacific in Green Salon-3. The presentation is part of a two-day panel program on the latest topics and developments in NASH/PBC drug development.
Dr. Song will also give a corporate presentation at the H.C. Wainwright & Co. Second Annual NASH Investor Conference taking place at the St. Regis Hotel in New York. The presentation will take place Monday, March 19, 2018 at 4:40 p.m. Eastern.
Metacrine is a privately held biotechnology company headquartered in San Diego, CA. The company is focused on efficiently developing innovative drugs that materially benefit patients with metabolic disease. For more information, visit www.metacrine.com.